| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/26/2004 | US20040040049 Reduction in the formation of the complex in the presence of the candidate agent as compared with in the absence of candidate agent indicates the candidate agent inhibits the binding of LBP-2 to the LBP-2 binding molecule |
| 02/26/2004 | US20040040047 Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| 02/26/2004 | US20040039376 Sustained delivery of an active agent using an implantable system |
| 02/26/2004 | US20040039186 Self-regulated apoptosis of inflammatory cells by gene therapy |
| 02/26/2004 | US20040039184 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
| 02/26/2004 | US20040039173 G-protein-coupled receptor proteins characterized by having sufficient binding affinity for corticotropin releasing factor(CRF) such that concentrations of # 10 nM of CRF occupy 350% of the binding sites of said receptor protein |
| 02/26/2004 | US20040039170 Regulation of human g protein-coupled receptor |
| 02/26/2004 | US20040039169 BASB202 polypeptides and polynucleotides encoding BASB202 polypeptides and methods for producing such polypeptides by recombinant techniques; diagnostic, prophylactic and therapeutic uses |
| 02/26/2004 | US20040039167 Derivatives of maurotoxin and of particular toxins belonging to the same structural class of K+ channel-acting short-chain scorpion toxins (less than 40 amino acid residues) that are cross-linked by four disulfide bridges; nerve disorder therapy |
| 02/26/2004 | US20040039165 Clostridium difficile polypeptides and uses thereof |
| 02/26/2004 | US20040039164 Invention relates to identification and isolation of novel DNA and to recombinant production of novel polypeptides |
| 02/26/2004 | US20040039163 Methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins |
| 02/26/2004 | US20040039162 Gdf-1 |
| 02/26/2004 | US20040039160 Comprises therapeutic agent, oligopeptide having an isoleucine residue, stabilizing group, and, optionally, a linker group; prodrug is cleavable by an enzyme associated with target cell; antitumor agents |
| 02/26/2004 | US20040039157 Derived from fibrinogen; gene therapy; animal models |
| 02/26/2004 | US20040039156 Comprises fusion proteins isolated from influenza virus hemagglutinin and colony stimulating factor |
| 02/26/2004 | US20040039066 Administering hydroxytyrosol and oleuropein in a ratio of 1:1-200:1 |
| 02/26/2004 | US20040039055 Ameliorate the negative side effects of a serum concentration of a drug higher than that used in normal clinical practice |
| 02/26/2004 | US20040039053 Administering to a patient a (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives or salt, free of its (+) stereoisomer to treat the type II diabetes, gout, insulin resistance and atherosclerosis |
| 02/26/2004 | US20040038963 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
| 02/26/2004 | US20040038958 Topical treatment of skin diseases |
| 02/26/2004 | US20040038945 Administering pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound. |
| 02/26/2004 | US20040038932 Antithrombotic compositions |
| 02/26/2004 | US20040038926 Antisense modulation of MyD88 expression |
| 02/26/2004 | US20040038924 Adenovirus serotype 30 (Ad30) |
| 02/26/2004 | US20040038921 Comprises double-stranded oligoribonucleic acid (dsRNA); hammerhead ribozymes |
| 02/26/2004 | US20040038920 Which stimulate lymphoctyes specific for myelin basic protein (MBP) autoantigen, which induces severe experimental autoimmune encephalomyelitis in animal models; cytokines |
| 02/26/2004 | US20040038919 Novel gene therapy agent for haemophilia b and its preparation method |
| 02/26/2004 | US20040038918 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| 02/26/2004 | US20040038908 Molecules that block viral infectivity and methods of use thereof |
| 02/26/2004 | US20040038907 For healing wounds/tissue repair |
| 02/26/2004 | US20040038906 Endothelin antagonist |
| 02/26/2004 | US20040038905 Anticancer agents |
| 02/26/2004 | US20040038903 Gonadotropin releasing hormone antagonists in gel-forming concentration |
| 02/26/2004 | US20040038902 For therapy of neoplastic disease |
| 02/26/2004 | US20040038900 For therapy of diabetes and other insulin-requiring states, hypoglycemia |
| 02/26/2004 | US20040038899 Polymer stabilized neuropeptides |
| 02/26/2004 | US20040038898 Contacting or admixing with the extracorporeal circulating blood with a Factor IXa compound in an amount effective to inhibit thrombosis |
| 02/26/2004 | US20040038897 Stimulates a sexual and/or erectile response in a mammal |
| 02/26/2004 | US20040038895 For diagnosis and therapy of respiratory and inflammatory diseases |
| 02/26/2004 | US20040038894 Useful for modulating an animal cell function involved in a disease selected from immunoproliferative diseases, immunodeficiency diseases, cancers, autoimmune diseases, infectious diseases, viral diseases, inflammatory response |
| 02/26/2004 | US20040038893 Prevention and reduction of blood loss |
| 02/26/2004 | US20040038891 Contacting the tissue or organ with an effective amount of an apolipoprotein to treat, prevent or reduce ischemic reperfusion injury |
| 02/26/2004 | US20040038889 Fumaric acid amides |
| 02/26/2004 | US20040038888 Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells |
| 02/26/2004 | US20040038887 Copolymers for suppression of autoimmune diseases, and methods of use |
| 02/26/2004 | US20040038886 Chimeric cytoplasmic signalling molecules derived from cd137 |
| 02/26/2004 | US20040038885 Carriers for administration of active principles such as drugs or nutriments, cosmetic products or plant health products such as herbicides, pesticides, insecticides, fungicides, etc. |
| 02/26/2004 | US20040038884 Treatment of tinitus |
| 02/26/2004 | US20040038883 To induce apoptosis in cells and sensitize tumor cells to cancer therapies |
| 02/26/2004 | US20040038882 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 02/26/2004 | US20040038881 For diagnosis, therapy and prophylaxis of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders |
| 02/26/2004 | US20040038880 Brain associated inhibitor of tissue - type plasminogen activator |
| 02/26/2004 | US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure |
| 02/26/2004 | US20040038878 Injectable protein formulations |
| 02/26/2004 | US20040038877 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/26/2004 | US20040038876 For use in therapy and diagnosis |
| 02/26/2004 | US20040038874 Inhibiting the biochemical mediators of inflammation in a subject comprising administering to subject therapeutically effective dosage of inhibitor |
| 02/26/2004 | US20040038873 Used for the manufacture of medicine for the treatment of developmental disorders, diseases caused by abnormal metabolism of immune system, and cancers |
| 02/26/2004 | US20040038872 Inhibitors of hepatitis C virus |
| 02/26/2004 | US20040038869 Inhibitors of complement activation, their preparation and use |
| 02/26/2004 | US20040038868 Administering, by way of the patient's trachea, to the target region of the patient's lung, an anti-surfactant, whereafter the target region collapses and one portion of the target region adheres to another portion of the target region |
| 02/26/2004 | US20040038864 Use of dimethyl sulfone as isotonicity agent |
| 02/26/2004 | US20040038863 Therapy of growth failure in an individual, comprising administering to the individual an aromatase inhibitor |
| 02/26/2004 | US20040038861 Methods and compositions for normalizing lipid levels in mammalian tissues |
| 02/26/2004 | US20040038859 Containing stabilizing agent comprising matrix metalloproteinase inhibitor |
| 02/26/2004 | US20040038404 Comprises deletion in adenovirus-2 early region 1A gene; for expression of a protein effective in regulating the cell cycle (such as p53, mitosin, or thymidine kinase suicide genes); tumor suppressor genes/proteins |
| 02/26/2004 | US20040038381 Comprises genetically engineered strains of Pichia; mannosidases; glycoproteins; kits |
| 02/26/2004 | US20040038379 Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |
| 02/26/2004 | US20040038370 Claudin polypeptides |
| 02/26/2004 | US20040038364 Such as snake venom proteases; anticoagulants |
| 02/26/2004 | US20040038363 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | US20040038362 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | US20040038361 Novel protein kinase (NPK-110) |
| 02/26/2004 | US20040038349 Heteromultimeric TNF ligand family members |
| 02/26/2004 | US20040038348 Synthetic heparin-binding growth factor analogs |
| 02/26/2004 | US20040038347 Apoptosis inducing molecule I |
| 02/26/2004 | US20040038346 Vectors, host cells, and recombinant methods for making and using the novel molecules |
| 02/26/2004 | US20040038345 Discovery, identification and characterization of novel human polynucleotides that encode membrane associated proteins and receptors |
| 02/26/2004 | US20040038343 Used in the diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections |
| 02/26/2004 | US20040038341 Chimeric human-type vascular endothelial cell growth factor |
| 02/26/2004 | US20040038339 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 02/26/2004 | US20040038336 Identification and isolation of novel DNA and to the recombinant production of novel polypeptides |
| 02/26/2004 | US20040038335 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/26/2004 | US20040038325 Adhesion molecules |
| 02/26/2004 | US20040038323 Inhibitors of cell migration and shape changes by inhibiting cortactin and hs-1 medicated actin polymerization |
| 02/26/2004 | US20040038322 Preventing metastasis and tumor expression via gene expression inhibition of kruppel like transcription factor; antisense therapy; antitumor agents; gene silencing agents |
| 02/26/2004 | US20040038313 Inhibitors of agonist-specific desensitization |
| 02/26/2004 | US20040038302 Using fragment, mimetic and/or a derivative of amyloid precursor protein (APP) to treat neurodegenerative diseases |
| 02/26/2004 | US20040038297 Masp-2,a complement-fixing enzyme, and uses for it |
| 02/26/2004 | US20040038288 Human protein C Polypeptide |
| 02/26/2004 | US20040038285 Comprises polypeptide which possess hematopoietic, tissue generative/regeneration, activin/inhibin, chemotactic, hemostatic and thrombolytic activity for prevention and treatment autoimmune, viral and tumor disorders |
| 02/26/2004 | US20040038284 Using replication error phenotype (RER) to classify and prognose tumor disorders; immunoassay |
| 02/26/2004 | US20040038279 Comprises ubiquitin conjugating enzyme for diagnosis, prevention and treatment of cell proliferative, immunological, neurological, and reproductive disorders |
| 02/26/2004 | US20040038277 Comprises nucleotide sequences coding polypeptides containing signal sequences for diagnosis, prevention and treatment of reproductive, lung, blood, tumor, respiratory and autoimmune diseases |
| 02/26/2004 | US20040038276 Comprises nucleotide sequences coding cytokines for diagnosis, prevention and treatment of spinocerebellar ataxia, psychological and nervous system disorders |
| 02/26/2004 | US20040038275 Human frezzled-like protein |
| 02/26/2004 | US20040038274 Gapped 2' modified oligonucleotides |
| 02/26/2004 | US20040038271 Novel C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/26/2004 | US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets |